Intech Biopharm Ltd

Intech Biopharm Ltd

TTPEX:6461
27.25
TWD
+2.45
(+9.88%)
-4.79EPS
1.67BMarket Cap

Total Valuation

TWD

As of September 30, 2026, Intech Biopharm Ltd carries a market capitalization of 1.67B, placing it among publicly traded companies globally. Its enterprise value stands at 2.95B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.67B
Enterprise Value2.95B

Share Statistics

As of September 30, 2026, Intech Biopharm Ltd has 68.24M shares outstanding.

Shares Outstanding68.24M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 44.55, and the price-to-book ratio stands at 2.20.

PS Ratio44.55
PB Ratio2.20
P/TBV Ratio2.23
P/FCF Ratio-6.77
P/OCF Ratio-7.74

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 54.34 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.95B versus a market cap of 1.67B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales54.34

Financial Position

As of September 30, 2026, Intech Biopharm Ltd maintains a current ratio of 1.85, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 210.92, indicating elevated leverage, while an interest coverage ratio of -11.11 demonstrates limited ability to service its debt obligations.

Current Ratio1.85
Quick Ratio1.12
Debt / Equity210.92
Debt / EBITDA-4.41
Interest Coverage-11.11

Financial Efficiency

TWD

Over the twelve months ended September 30, 2026, Intech Biopharm Ltd posted a negative return on equity (ROE) of -54.37, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -19.25, reflecting losses generated across the asset base. The company generates approximately 662,719.51 in revenue per employee across its workforce of 82.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.99 indicates how many times Intech Biopharm Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-54.37
Return on Assets (ROA)-19.25
Revenue Per Employee662,719.51
Employee Count82.00
Inventory Turnover1.99

Stock Price Statistics

TWD

As of the close on November 17, 2026, Intech Biopharm Ltd's stock has gained approximately 11.53% over the past 52 weeks. The 50-day moving average sits at 26.41, while the 200-day moving average is 28.31.

52-Week Price Change11.53%
50-Day Moving Average26.41
200-Day Moving Average28.31

Income Statement

TWD

Over the twelve months ended September 30, 2026, Intech Biopharm Ltd generated 54.34M in revenue and converted that into -474.56M in net income, yielding earnings per share of -4.79. EBITDA reached -362.23M, while operating income came in at -455.72M.

Revenue54.34M
Gross Profit-192.10M
Operating Income-455.72M
Pretax Income-474.56M
Net Income-474.56M
EBITDA-362.23M
EBIT-455.72M
Earnings Per Share (EPS)-4.79

Balance Sheet

TWD

As of September 30, 2026, Intech Biopharm Ltd holds 313.68M in cash and equivalents against 1.60B in total debt, resulting in a net debt position of 1.42B. Total book value stands at 757.78M, with working capital of 238.95M providing operational flexibility.

Cash & Cash Equivalents313.68M
Total Debt1.60B
Net Debt1.42B
Equity (Book Value)757.78M
Book Value Per Share11.10
Working Capital238.95M

Cash Flow

TWD

Intech Biopharm Ltd produced -312.87M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -44.63M in capital expenditures, free cash flow totaled -357.50M - equivalent to -3.61 per share.

Operating Cash Flow-312.87M
Capital Expenditures-44.63M
Free Cash Flow-357.50M
FCF Per Share-3.61

Margins

Over the twelve months ended September 30, 2026, Intech Biopharm Ltd posted a gross margin of -353.50, reflecting its pricing power and cost economics. The operating margin of -838.60 and net profit margin of -873.26 provide insight into operational efficiency.

Gross Margin-353.50
Operating Margin-838.60
Pretax Margin-873.26
Profit Margin-873.26
EBITDA Margin-666.57

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -14.77: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -21.11, meaning Intech Biopharm Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-21.11
FCF Yield-14.77

Stock Splits

Intech Biopharm Ltd's most recent stock split took place on September 2, 2026 with a 500:309 split ratio.

Last Split Date9/2/2026
Split Ratio500:309

Scores

As of September 30, 2026, Intech Biopharm Ltd has an Altman Z-Score of -0.09, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-0.09